Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2007 Nov 23;25(48):8180-9. Epub 2007 Oct 5.

Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.

Author information

1
AlphaVax, Inc., 2 Triangle Drive, Research Triangle Park, NC 27709, USA.

Abstract

We used a propagation-defective, single-cycle, alphavirus replicon vector system to produce virus-like replicon particles (VRP) expressing the hemagglutinin (HA) and neuraminidase (NA) proteins from influenza A/Wyoming/03/2003 (H3N2). Efficient production methods were scaled to produce pilot lots of HA VRP and NA VRP and clinical lots of HA VRP. HA VRP-induced high-titered antibody responses in mice, rabbits and rhesus macaques, as measured by ELISA or hemagglutination inhibition (HI) assays, and robust cellular immune responses in mice and rhesus macaques, as measured by IFN-gamma ELISPOT. NA VRP also induced cellular immune responses in mice. A toxicology study with HA VRP and NA VRP in rabbits showed no adverse effects in any parameter. These studies support clinical testing of alphavirus replicon vaccines for influenza.

PMID:
17961878
PMCID:
PMC2706696
DOI:
10.1016/j.vaccine.2007.09.038
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center